CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Sep. 1, 2021-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ®) technology, today announced that management will

-        Entered exclusive license and collaboration agreement with Ionis Pharmaceuticals to develop targeted oligonucleotide therapeutics -        Cash was $198.7 million as of June 30 , 20 21, which excludes $71.9 million received in July from both the Ionis collaboration upfront and net proceeds

- Bicycle to receive a total of $45 million upfront from Ionis and is eligible for development, regulatory and commercial milestone payments and royalties - The agreement provides Ionis an exclusive license to Bicycles that bind with high specificity to the transferrin receptor without modifying

CAMBRIDGE, England , & BOSTON --(BUSINESS WIRE)--Jun. 15, 2021-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced an update regarding

CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--May 27, 2021-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that management will

- BT7480, the lead Bicycle tumor-targeted immune cell agonist, presented at AACR Annual Meeting 2021 “New Drugs on the Horizon” session; remains on-track for 2H'21 clinical trial start - Achieved significant recent progress across pipeline of Bicycle ®-based therapies beyond oncology - Raised $75.0

- BT7480 to be presented in a “New Drugs on the Horizon” session; on-track to enter the clinic in 2H’21 CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Apr. 10, 2021-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on

- First milestone achieved in neuroscience collaboration with Dementia Discovery Fund and the Alzheimer’s Research UK Oxford Drug Discovery Institute - Significant advances made in the application of Bicycle technology against emerging antimicrobial and antiviral targets - Additional Bicycles

CAMBRIDGE, England , & BOSTON --(BUSINESS WIRE)--Mar. 18, 2021-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced the appointment of

CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Mar. 11, 2021-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ®) technology, today announced that management will